-
Lilly diabetes drug is approved for adult weight loss in the United States, and its price is 20% cheaper than that of Pinot Noir and Nordisk
GLP-1 drugs have gained significant players in the field of weight loss, with prices 20% cheaper than Nuo and Nordsmiglutide. On November 8 local time, Eli Lilly, a multinational pharmaceutical giant ... -
AstraZeneca elontersen approved in the United States
On December 21st local time, AstraZeneca announced that its and Ionis company's eplontersen have been approved in the United States. Eplontersen is an antisense oligonucleotide (ASO) therapy for the ... -
Approval of new indications for Mercado Pembrolizumab
On February 4th, Merck&Company announced that its PD-1 inhibitor pembrolizumab has been approved by the National Medical Products Administration (NMPA) of China for first-line treatment in combinatio ... -
AstraZeneca IL-5R α monoclonal antibody approved for market in China
On August 19th, according to the official website of the National Medical Products Administration, AstraZeneca's IL-5R alpha monoclonal antibody (benralizumab) has been approved for listing in China. ... -
Lilly claims that the weight loss drug Mounjaro has been approved for sale in Hong Kong
On October 28, Lilly said in a statement that it had obtained the approval of the Hong Kong SAR government to sell its Tirzepatide injection (trade name: Mounjaro) through a device called Kwikpen (pr ... -
Merck antifungal drug Noclof é l? New indications approved
On December 10th, Southern Finance and Economics reported that Merck announced the use of its antifungal drug, NozoNobel&Co; reg; The new indications for two dosage forms, Bosaconazole enteric coated ...